Table Of Contents
1. Market Context & Strategic Relevance
1.1 Opening Context (Why the market matters)
1.1.1 Why This Market Is Gaining Strategic Attention
1.1.2 Business Decisions This Report Supports
1.2 Scope
1.3 Research & Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035
2.3 Market Size & Forecast, By Segmentation, 2022–2035
2.3.1 Market Size by Technology
2.3.2 Market Size by Application
2.3.3 Market Size by End User
2.4 Market Share & Bps Analysis by Region, 2025
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material & Nucleic Acid Component Suppliers
3.4.2 Nucleic Acid Therapeutics Developers & Manufacturers
3.4.3 Contract Development & Manufacturing Organizations
3.4.4 Distributors & Healthcare Providers
3.5 Industry Life Cycle Assessment
4. Statistical Insights & Trends Reporting
4.1 Nucleic Acid Therapeutics Development & Adoption Trends (2025)
4.1.1 Global Nucleic Acid Therapeutics Clinical Development Statistics
4.1.2 Approved Nucleic Acid Therapeutics & Pipeline Trends
4.1.3 RNA-Based vs. DNA-Based Therapeutics Development Trends
4.1.4 Therapeutic Area-Wise Adoption Analysis
4.2 Clinical Trials & Regulatory Trends (2025)
4.2.1 Nucleic Acid Therapeutics Clinical Trial Activity
4.2.2 Regulatory Approvals & Product Launch Trends
4.2.3 Phase-Wise Clinical Development Analysis
4.2.4 Orphan & Rare Disease Therapeutics Development Trends
4.3 Nucleic Acid Delivery & Technology Trends (2025)
4.3.1 Lipid Nanoparticle-Based Delivery Adoption Trends
4.3.2 Viral & Non-Viral Delivery Technology Trends
4.3.3 Targeted Delivery & Tissue-Specific Technologies
4.3.4 Next-Generation Nucleic Acid Delivery Innovation Trends
4.4 Therapeutic Application & Disease Trends (2025)
4.4.1 Oncology Nucleic Acid Therapeutics Development Trends
4.4.2 Genetic & Rare Disease Treatment Trends
4.4.3 Infectious Disease & Vaccine-Related Applications
4.4.4 Cardiovascular & Metabolic Disease Application Trends
4.5 Technology, Investment & Commercialization Trends (2025)
4.5.1 RNA Interference, Antisense & mRNA Technology Trends
4.5.2 Gene Editing & Gene Silencing Innovation Trends
4.5.3 R&D Investment & Strategic Partnership Trends
4.5.4 Manufacturing Capacity & Commercialization Trends
5. Nucleic Acid-based Therapeutics Market Segmental Analysis & Forecast, By Technology, 2022–2035, Value (USD Billion)
5.1 Introduction
5.2 RNA-Targeted Therapeutics
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2022–2035
5.3 Gene Therapies
5.4 Genome Editing Therapies
5.5 Epigenetic & microRNA Modulating Therapies
6. Nucleic Acid-based Therapeutics Market Segmental Analysis & Forecast, By Application, 2022–2035, Value (USD Billion)
6.1 Introduction
6.2 Genetic Disorders
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2022–2035
6.3 Cancer
6.4 Infectious Diseases
6.5 Autoimmune Disorders
7. Nucleic Acid-based Therapeutics Market Segmental Analysis & Forecast, By End User, 2022–2035, Value (USD Billion)
7.1 Introduction
7.2 Hospitals & Clinics
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2022–2035
7.3 Academic & Research Institutes
7.4 Others
8. Nucleic Acid-based Therapeutics Market Segmental Analysis & Forecast By Region, 2022–2035, Value (USD Billion)
8.1 Introduction
8.2 North America
8.2.1 Key Trends
8.2.2 Nucleic Acid-based Therapeutics Market Size & Forecast, By Technology, 2022–2035
8.2.3 Nucleic Acid-based Therapeutics Market Size & Forecast, By Application, 2022–2035
8.2.4 Nucleic Acid-based Therapeutics Market Size & Forecast, By End User, 2022–2035
8.2.5 Nucleic Acid-based Therapeutics Market Size & Forecast, By Country, 2022–2035
8.2.5.1 USA
8.2.5.2 Canada
8.3 Europe
8.3.1 Key Trends
8.3.2 Nucleic Acid-based Therapeutics Market Size & Forecast, By Technology, 2022–2035
8.3.3 Nucleic Acid-based Therapeutics Market Size & Forecast, By Application, 2022–2035
8.3.4 Nucleic Acid-based Therapeutics Market Size & Forecast, By End User, 2022–2035
8.3.5 Nucleic Acid-based Therapeutics Market Size & Forecast, By Country, 2022–2035
8.3.5.1 Germany
8.3.5.2 UK
8.3.5.3 France
8.3.5.4 Italy
8.3.5.5 Spain
8.3.5.6 Russia
8.3.5.7 Poland
8.3.5.8 Rest of Europe
8.4 Asia-Pacific
8.4.1 Key Trends
8.4.2 Nucleic Acid-based Therapeutics Market Size & Forecast, By Technology, 2022–2035
8.4.3 Nucleic Acid-based Therapeutics Market Size & Forecast, By Application, 2022–2035
8.4.4 Nucleic Acid-based Therapeutics Market Size & Forecast, By End User, 2022–2035
8.4.5 Nucleic Acid-based Therapeutics Market Size & Forecast, By Country, 2022–2035
8.4.5.1 China
8.4.5.2 India
8.4.5.3 Japan
8.4.5.4 South Korea
8.4.5.5 Australia
8.4.5.6 ASEAN Countries
8.4.5.7 Rest of Asia-Pacific
8.5 Latin America
8.5.1 Key Trends
8.5.2 Nucleic Acid-based Therapeutics Market Size & Forecast, By Technology, 2022–2035
8.5.3 Nucleic Acid-based Therapeutics Market Size & Forecast, By Application, 2022–2035
8.5.4 Nucleic Acid-based Therapeutics Market Size & Forecast, By End User, 2022–2035
8.5.5 Nucleic Acid-based Therapeutics Market Size & Forecast, By Country, 2022–2035
8.5.5.1 Brazil
8.5.5.2 Argentina
8.5.5.3 Mexico
8.5.5.4 Colombia
8.5.5.5 Rest of Latin America
8.6 Middle East & Africa
8.6.1 Key Trends
8.6.2 Nucleic Acid-based Therapeutics Market Size & Forecast, By Technology, 2022–2035
8.6.3 Nucleic Acid-based Therapeutics Market Size & Forecast, By Application, 2022–2035
8.6.4 Nucleic Acid-based Therapeutics Market Size & Forecast, By End User, 2022–2035
8.6.5 Nucleic Acid-based Therapeutics Market Size & Forecast, By Country, 2022–2035
8.6.5.1 UAE
8.6.5.2 Saudi Arabia
8.6.5.3 Qatar
8.6.5.4 South Africa
8.6.5.5 Rest of Middle East & Africa
9. Competitive Landscape
9.1 Key Players' Positioning
9.2 Competitive Developments
9.2.1 Year-Wise Strategies & Development, 2022–2026
9.3 Market Share Analysis, 2025
9.4 Product/Service & Application Benchmarking
9.4.1 Product/Service Specifications & Features By Key Players
9.4.2 Product/Service Heatmap By Key Players
9.4.3 Application Heatmap By Key Players
9.5 Industry Start-Up & Innovation Landscape
9.6 Key Company Profiles
9.6.1 Alnylam Pharmaceuticals Inc.
9.6.1.1 Company Overview & Snapshot
9.6.1.2 Product/Service Portfolio
9.6.1.3 Key Company Financials
9.6.1.4 Geographical Presence
9.6.1.5 SWOT Analysis
9.6.2 Ionis Pharmaceuticals Inc.
9.6.3 Moderna Inc.
9.6.4 BioNTech SE
9.6.5 Novartis Pharma AG
9.6.6 Sarepta Therapeutics Inc.
9.6.7 Silence Therapeutics plc
9.6.8 Wave Life Sciences Ltd.
9.6.9 Beam Therapeutics Inc.
9.6.10 Intellia Therapeutics Inc.
9.6.11 CRISPR Therapeutics AG
9.6.12 Arrowhead Pharmaceuticals Inc.
9.6.13 Protagonist Therapeutics Inc.
9.6.14 Biogen Inc.
9.6.15 Amgen Inc.
9.6.16 Pfizer Inc.
9.6.17 Regeneron Pharmaceuticals
9.6.18 Vertex Pharmaceuticals
9.6.19 Editas Medicine Inc.
9.6.20 Genevant Sciences
10. Analyst Recommendations
10.1 SNS Insider Opportunity Map
10.2 Industry Low-Hanging Fruit Assessment
10.3 Market Entry & Growth Strategy
10.4 Analyst Viewpoint & Suggestions On Market Growth
11. Assumptions
12. Disclaimer
13. Appendix
13.1 List Of Tables
13.2 List Of Figures
Frequently Asked Questions
Leading companies include Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Moderna Inc., BioNTech SE, and Novartis Pharma AG, among other major RNA therapeutics and genome editing biotechnology companies.
Opportunities include continued development of extrahepatic delivery systems reaching the central nervous system and muscle, rapid expansion of mRNA and RNA interference cancer immunotherapy pipelines, and growing CDMO investment in vertically integrated manufacturing capability
Growth is driven by increasing prevalence of genetic and chronic diseases, continued advances in genomics and molecular biology, growing R&D investment following mRNA platform validation, and rising demand for personalized precision medicine approaches.
RNA-Targeted Therapeutics dominates by technology with approximately 54.6% share, Genetic Disorders dominates by application with roughly 34.8% share, and Hospitals & Clinics dominates by end user with about 48.3% share; Genome Editing Therapies, Cancer, and Academic & Research Institutes are the fastest-growing segments within their respective categories.
North America is the largest regional market with approximately 46.0% share, led by the United States, while Asia Pacific, led by China, is the fastest-growing region through 2035.
